Sunlight streamed through the tall glass windows of the conference room, catching glints of silver off coffee pots and the rims of untouched water glasses. Around the large oval table, faces from all corners of the world sat in quiet focus — researchers, neurologists, geneticists, and a few psychologists — each brought here by Mara Shepherd's quiet determination.
She sat beside Steve, her hand gently resting on his, steady even as the discussion grew dense with technical language and guarded optimism.
Professor Arlen, the lead consultant Mara had personally reached out to in Zurich, was speaking. His voice, deep and deliberate, echoed faintly in the high-ceilinged room.
"Based on the scans and the behavioral data, I believe you're on the right track," he said. "The current combination of targeted neuro-stimulation and gene therapy is showing early signs of response. It's cautious hope — but it's still hope."
